Vivani Medical confirmed in an August 6, 2026 securities filing that all 20 subjects enrolled in SLIM-1 have been dosed — the first time a semaglutide implant has been put into humans. The product, NPM-139, is a miniature rod placed under the skin during a short outpatient procedure, engineered to release semaglutide at a controlled rate for six to twelve months instead of requiring an injection every week.
The trial is small and short by design. SLIM-1 runs four weeks in 20 GLP-1-naive adults with overweight or obesity in Australia, split evenly between a low-dose NPM-139 implant and weekly subcutaneous semaglutide 0.25 mg as an active comparator. It measures safety, tolerability and pharmacokinetics. It does not measure weight loss. What it will answer by year-end is narrower but more consequential than an efficacy number: whether the implant releases semaglutide into human blood at a predictable, non-bursting rate.
Research-context information only. Peptides and investigational products discussed below are research compounds or unapproved investigational drugs. Doses and outcomes reported come from published trial data and company disclosures. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
What Was Actually Announced
Three disclosures over five weeks moved NPM-139 from preclinical asset to clinical-stage program.
June 25, 2026 — ethics approval. An Australian human research ethics committee cleared SLIM-1 to proceed. Australia is a common venue for first-in-human pharmacokinetic work because the ethics-committee route is faster than a US IND for a small early-phase study.
July 7, 2026 — Novo Nordisk evaluation agreement. Vivani announced that Novo Nordisk would conduct a non-exclusive internal evaluation of NPM-139. The company's release is explicit that the agreement "contains no exclusivity provisions for NPM-139, or Vivani's proprietary NanoPortal technology," and no financial terms were disclosed. This is a look-and-assess arrangement, not a licensing deal — but the party doing the looking is the company that manufactures semaglutide.
August 6, 2026 — all subjects dosed. Vivani filed an 8-K confirming completion of dosing across all 20 enrolled subjects. Enrollment and dosing were completed close together, which tightens the pharmacokinetic sampling window and makes the cross-subject comparison cleaner. Topline data is guided for by the end of 2026.
The number to watch when SLIM-1 reads out is not a weight figure. It is the spread of semaglutide plasma concentrations across the ten implanted subjects. Tight clustering means the polymer is metering the drug the way the bench data predicted, and the platform advances. Wide scatter means individual subjects would receive materially different doses from an identical implant — a reformulation problem, and the failure mode that has historically killed long-acting implant programs.
Why an Implant, and What the Prior Data Shows
The problem NPM-139 targets is not potency. It is that people stop.
In a cohort of 125,474 US adults initiating GLP-1 receptor agonists, 46.5 percent of those with type 2 diabetes and 64.8 percent of those without had discontinued within one year (Rodriguez et al., JAMA Network Open 2025, PMID 39888616). Weekly self-injection is not the only reason — cost, side effects and supply all contribute — but it is the one a delivery-system change can address directly. An implant collapses 52 dosing decisions a year into one clinic visit.
Two datasets underpin the program.
Preclinical NPM-139. Vivani's March 2025 release reported roughly 20 percent placebo-adjusted weight reduction from a single administration over a 91-day period in rats, with continuous non-fluctuating release and therapeutic exposure persisting for six months. Later disclosures extended the exposure and sham-adjusted weight-loss signal to a full year, and in vitro chemical and physical stability measured past twelve months is the specific basis for the once-yearly framing.
LIBERATE-1, the platform's first human test. Before NPM-139, Vivani ran NPM-115 — an exenatide implant on the same NanoPortal platform — through a Phase 1 first-in-human study. Vivani reported that the study met its primary objectives across nine weeks with no serious adverse events, and that the pharmacokinetic analysis supported drug release without a clinically meaningful burst. The company also cited the absence of gastrointestinal adverse events in implanted subjects as corroborating evidence that peak concentrations stayed flat. These are sponsor-disclosed results, not a peer-reviewed publication. LIBERATE-1 is why the platform earned a semaglutide program.
The honest read: the delivery technology has one clean human safety-and-PK dataset behind it, at nine weeks, with a different peptide. SLIM-1 is the first time semaglutide itself goes into the device in a person, and it runs four weeks. Everything about durable year-long delivery in humans remains unproven.
Where This Sits Against the Rest of the Field
Long-acting dosing is the most crowded engineering race in obesity right now, and it splits into two tiers.
| Candidate | Sponsor | Approach | Interval | Stage |
|---|---|---|---|---|
| NPM-139 | Vivani | Subdermal semaglutide implant | 6-12 months | Phase 1 (SLIM-1, n=20) |
| MariTide | Amgen | Peptide-antibody conjugate | Monthly | Phase 3 |
| PF-3944 | Pfizer | Biased GLP-1 agonist | Monthly | Phase 3 |
| MBX 4291 | MBX Biosciences | GLP-1/GIP peptide prodrug | Monthly | Phase 1 |
The monthly programs re-engineer the molecule so it clears the body more slowly. The implant leaves the molecule alone and re-engineers the container. That difference matters commercially: Amgen's MariTide, Pfizer's PF-3944 and MBX 4291 each need their own full efficacy program because each is a new chemical entity. NPM-139 delivers semaglutide, a molecule with a decade of outcome data behind it, which is the argument for a shorter development path — offset by the device-plus-drug regulatory pathway an implant has to clear and a plain injectable does not.
It also sits at the opposite end of the field from where efficacy is headed. Weekly retatrutide reported 28.7 percent mean weight loss at 68 weeks in TRIUMPH-4; weekly tirzepatide reported approximately 21 percent at 72 weeks in SURMOUNT-1 (PMID 35658024); weekly semaglutide reported approximately 15 percent at 68 weeks in STEP 1 (PMID 33567185). An implant delivering semaglutide is anchored to the lowest of those three ceilings. It competes on adherence, not magnitude — and only for people for whom adherence, rather than result, is the binding constraint.
What This Means for Buyers Today
Nothing about SLIM-1 changes what is purchasable now, and the reason is worth spelling out because it is permanent rather than a matter of timing.
An implant is not a molecule, so the research market cannot mirror it. Every compound in a research vendor catalog is lyophilized powder in a vial — the buyer supplies the bacteriostatic water and the syringe. That model works because the value is in the peptide itself. NPM-139's value is in the polymer body metering the release rate; the semaglutide inside is the commodity part. There is no version of a research vendor shipping a NanoPortal implant, and no compounding pharmacy pathway for one either. When people ask which vendor will carry the implant, the answer is none, ever.
The timeline is long even in the best case. SLIM-1 is a four-week, 20-subject pharmacokinetic study. Dose-finding, a powered efficacy program and FDA review all sit downstream of a clean readout, and combination device-drug products historically add review time rather than save it.
What actually moves for a buyer right now is price, not pipeline. Weekly semaglutide, tirzepatide and retatrutide remain the compounds with live vendor pricing, and that pricing moves week to week as vendors run promotions against one another.
